4.7 Article

Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome

Journal

BLOOD
Volume 115, Issue 19, Pages 3966-3969

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-09-242107

Keywords

-

Categories

Funding

  1. Australian National Health and Medical Research Council [461219, 516726, 361646]
  2. Australian Research Council
  3. Sylvia and Charles Viertel Charitable Foundation
  4. Cancer Council, Victoria
  5. Australian Department of Education, Science and Training
  6. Haematology Society of Australia and New Zealand
  7. Leukemia Foundation of Australia
  8. Australian Cancer Research Fund
  9. Victorian State Government

Ask authors/readers for more resources

Down syndrome is characterized by multiple phenotypic manifestations associated with trisomy of chromosome 21. The transient myeloproliferative disorder and acute megakaryocytic leukemia associated with Down syndrome are uniquely associated with mutations in the transcription factor GATA1; however, the identity of trisomic genes on chromosome 21 that predispose to these hematologic disorders remains unknown. Using a loss-of-function allele, we show that specific reduction to functional disomy of the Erg gene corrects the pathologic and hematologic features of myeloproliferation in the Ts(17(16))65Dn mouse model of Down syndrome, including megakaryocytosis and progenitor cell expansion. Our data provide genetic evidence establishing the need for Erg trisomy for myeloproliferation in Ts(17(16))65Dn mice and imply that increased ERG gene dosage may be a key consequence of trisomy 21 that can predispose to malignant hematologic disorders in Down syndrome. (Blood. 2010; 115(19): 3966-3969)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available